OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer

REDWOOD CITY, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED ), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's " PINNACLE " clinical trial of its anti-Notch2/3 cancer stem cell antibody, tarextumab (OMP-59R5), for the treatment of small cell lung cancer (SCLC).

Tarextumab is being studied in combination with chemotherapy in patients with previously untreated, extensive stage SCLC. The randomized Phase 2 trial will compare progression-free survival (PFS) outcomes for patients treated with tarextumab administered at 15 mg/kg every two weeks in combination with etoposide and cisplatin or carboplatin versus patients who receive chemotherapy alone. Additionally, PFS will be assessed using a predictive biomarker for high tumor Notch3 expression. OncoMed scientists have determined that high tumor Notch3 expression is estimated to occur in about 60 percent of small cell lung cancer patients. Secondary endpoints for the Phase 2 study include overall survival, overall response rate, pharmacokinetics, safety and other biomarkers. The PINNACLE study is being conducted at about 40 sites in the U.S. and is expected to enroll approximately 130 patients. 

"Small cell lung cancer is a devastating disease and patients are in need of new treatment options," said Jakob Dupont, M.D., OncoMed's Chief Medical Officer. "Based on the manageable safety profile and the early response data observed in the Phase 1b portion of the PINNACLE study, we are excited to advance tarextumab into the randomized Phase 2 portion of this clinical trial. As reported in September at the 2014 ESMO Congress, tarextumab has been well tolerated and does not appear to add significant toxicities to standard-of-care chemotherapies.  Additionally, partial responses were observed in 13 of 16 evaluable patients."

OncoMed has completed enrollment in the Phase 1b portion of the PINNACLE study, which was designed to establish a maximum-tolerated dose for tarextumab when administered in combination with etoposide and cisplatin or carboplatin. Phase 1b PINNACLE data in patients with small cell lung cancer was reported at the European Society of Medical Oncology (ESMO) Congress 2014 in September 2014. Tarextumab was well tolerated in combination with etoposide and cisplatin. Of sixteen patients evaluable for efficacy, thirteen achieved partial responses (81.3%) and the remaining three patients achieved stable disease for a clinical benefit rate of 100 percent.

"We are driving all of our pipeline programs toward advanced clinical read-outs and partner opt-ins," said Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer. "This is the second of four randomized Phase 2 programs expected to begin by late 2014 or early 2015. In addition to tarextumab in SCLC and pancreatic cancer, which are both now under way, we are very close to enrolling patients in randomized studies of our anti-DLL4 antibody, demcizumab, in pancreatic and non-small cell lung cancer.  Our aim is to have multiple randomized Phase 2 data results between now and by the end of 2016."

About Small Cell Lung Cancer

According to the American Cancer Society, lung cancer (both small cell and non-small cell) is the second most common cancer in men and women and is by far the leading cause of cancer death. Small cell lung cancer is expected to make up about 10%-15% of the 224,210 newly diagnosed lung cancer cases and the 159,260 deaths estimated to occur in the U.S. in 2014 1 . SCLC tends to grow and spread quickly, and is typically not discovered until it has metastasized to other parts of the body (extensive stage). The current standard of care in treating small cell lung cancer is the chemotherapeutic etoposide in combination with either cisplatin or caboplatin. In spite of a high sensitivity to chemotherapy and remission rates of up to 80% following initial treatment, the median overall survival is less than one year for patients with extensive stage disease 2 .

About Tarextumab (anti-Notch2/3, OMP-59R5)

Tarextumab (anti-Notch2/3, OMP-59R5) is a fully human monoclonal antibody that targets the Notch2 and Notch3 receptors. Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-CSC effects, and (2) tarextumab affects pericytes, impacting stromal and tumor microenvironment. Tarextumab is currently being studied in two randomized Phase 2 clinical trials. The " ALPINE " study (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety) is assessing tarextumab with Abraxane ® (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in first-line advanced pancreatic cancer patients. The " PINNACLE " study (A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer) is testing tarextumab in combination with etoposide and cisplatin and etoposide and carboplatin in first-line extensive stage small cell lung cancer patients. Tarextumab is part of OncoMed's collaboration with GlaxoSmithKline (GSK). GSK has an option to obtain an exclusive license to tarextumab during certain time periods through completion of the proof-of-concept Phase 2 trials.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed has filed an Investigational New Drug (IND) application for its anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83) and plans to file an IND application for anti-RSPO3 (OMP-131R10) in early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com .

1 http://www.cancer.org/cancer/lungcancer-small...statistics

2 Jänne PA, Freidlin B, Saxman S, et al. Cancer 2002; 95:1528-38.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including OncoMed's expectations regarding the ability of OncoMed to advance its anti-CSC product candidates in development, including the advancement of demcizumab into Phase 2 clinical trials; OncoMed's ability to drive all of its programs towards advanced clinical read-outs and partner opt-in; the timing of initiation of the Phase 2 clinical trials for demcizumab; the efficacy of tarextumab against SCLC; the tolerability of tarextumab at efficacious doses; the frequency of Notch3 expression in SCLC patients; the timing of the availability of Phase 2 clinical data for OncoMed's product candidates; the number of sites and patients enrolled in the PINNACLE clinical trial; and the timing of an Investigational New Drug application filing for OncoMed's anti-RSPO3 antibody. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; OncoMed's dependence on its collaboration partners, including Celgene, GSK and Bayer, for the funding of its partnered programs; OncoMed's ability to raise additional capital to support the development of its unpartnered programs; OncoMed's dependence on the development and marketing efforts of its partners for the commercial success of its partnered product candidates; OncoMed's reliance on third parties to conduct certain preclinical studies and all of its clinical trials; OncoMed's reliance on single source third-party contract manufacturing organizations to manufacture and supply its product candidates; OncoMed's ability to validate, develop and obtain regulatory approval for companion diagnostics; OncoMed's ability to achieve market acceptance and commercial success of its product candidates once regulatory approval is achieved; OncoMed's ability to discover, develop and commercialize additional product candidates; the ability of competitors to discover, develop or commercialize competing products more quickly or more successfully; OncoMed's dependence on its Chairman and Chief Executive Officer, its Chief Scientific Officer, its Chief Medical Officer and other key executives; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate OncoMed's patents or proprietary rights; and the ability of OncoMed's proprietary rights to protect its technologies and product candidates. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed's business in general, see OncoMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the Securities and Exchange Commission (SEC) on March 18, 2014, OncoMed's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014, filed with the SEC on May 8, 2014, OncoMed's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2014, filed with the SEC on August 7, 2014, and OncoMed's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2014, filed with the SEC on November 4, 2014.

OncoMed Pharmaceuticals Michelle Corral Investor Relations and Corporate Communications (650) 995-8373 Shari Annes Annes Associates (650) 888-0902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 165

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 75

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 7

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Markel's $2.5 Billion Buyback Adds Capital Flexibility

Updated Category News Views 86

A Large Checkbook, Not a Purchase Order Markel just handed management another $2.5 billion of repurchase firepower, and that deserves attention without the usual buyback cheerleading. The Board approved an increase to the existing authorization on November 18, 2026. That is a meaningful capital-allocation signal from a company built around specialty insurance,...

Continue Reading
Foresite's No. 22 Rank Signals MSSP Growth Momentum

Updated Category News Views 36

Cybersecurity rankings can be a carnival of shiny badges, but No. 22 out of 250 managed security providers is not something a serious buyer should casually brush aside. Foresite Cybersecurity landed there in MSSP Alert's 2026 survey and also made three of the program's new Prestige Top 10 lists: Best Enterprise Focused MSSP, Most Innovative MSSPs, and Fastest Growing...

Continue Reading
Cold Stone’s Holiday Menu Is a Franchisee Traffic Test

Updated Category News Views 88

Peppermint, caramel, and red velvet arrive right when dessert budgets loosen up. Cold Stone Creamery has rolled out a holiday menu running through January 5, 2027, and this is the sort of modest, practical promotion that matters more to a franchise system than the glittery language around it. Nobody should confuse two seasonal ice cream flavors with a corporate...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 74

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
M.O.L.I.F.E. Brings Community Inclusion Into Public View

Updated Category News Views 23

A food pantry can reveal more about inclusion than a polished mission statement ever will. M.O.L.I.F.E., Inc. is set to be featured in an educational segment of All Access with Andy Garcia, and the useful part of this story is not the celebrity-host packaging. It is the organization’s insistence that employment, independent living, day programming, residential support,...

Continue Reading

Top 5 Most Recently Viewed Articles

Arasan Chip Systems Unveils Advanced eUSB2 Solutions for IoT

Updated Category News Views 300

Arasan's Innovative USB2 Solutions Now Available Arasan Chip Systems, a recognized leader in semiconductor intellectual property for mobile and automotive systems on chips (SoCs), has announced the launch of its new Embedded USB2 (eUSB2) IP Core. This cutting-edge technology aims to empower a wide range of electronic devices with efficient connectivity options. Targeting...

Continue Reading
Class Action Filed Against MongoDB: Key Insights and Impacts

Updated Category News Views 98

Overview of the Class Action Lawsuit Against MongoDB Pomerantz LLP has recently brought attention to a significant legal issue concerning MongoDB, Inc. (NASDAQ: MDB). The law firm has filed a class action lawsuit that raises serious questions about the company's compliance with securities laws and the potential consequences for investors. Allegations Explained This...

Continue Reading
Rycor LLC's Strategic Push in Commercial Heating Solutions

Updated Category News Views 136

Expanding Horizons: Rycor LLC Enters Commercial Market RYCOR LLC, well-known as the Northeast's authority in energy-efficient residential mini-splits, is broadening its horizons to embrace the commercial heating and cooling sector. This strategic move represents a significant enhancement in their service offerings, targeting multi-family housing developments, office...

Continue Reading
Successful Charity Ride Brings Community Together for a Cause

Updated Category News Views 148

Second Annual Solstice Century Ride Makes a Big Impact During the longest day of the year, fifty-two enthusiastic riders took on a 100-mile challenge as they participated in the second annual Solstice Century Ride. The event, held at the picturesque Whalon Lake Forest Preserve, proved to be more than just a cycling challenge; it became a powerful avenue for community...

Continue Reading
QuickBooks' Intelligent AI Tool Revolutionizes Business Insights

Updated Category News Views 126

Revolutionizing Business Insights with Intelligent AI In today's fast-paced business environment, understanding how to leverage technology for better decision-making is crucial. Enter QuickBooks' Intelligent AI Dashboard Agent, a powerful tool that has been recognized by industry experts as the best all-in-one solution for real-time business insights in 2025. This...

Continue Reading